16,169 Shares in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH) Purchased by Los Angeles Capital Management LLC

Los Angeles Capital Management LLC acquired a new stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund acquired 16,169 shares of the company's stock, valued at approximately $785,000.

Other hedge funds and other institutional investors also recently added to or reduced their stakes in the company. TD Asset Management Inc lifted its holdings in shares of Amphastar Pharmaceuticals by 67.4% during the 2nd quarter. TD Asset Management Inc now owns 1,691,569 shares of the company's stock valued at $67,663,000 after buying an additional 680,976 shares during the period. Epoch Investment Partners Inc. boosted its position in Amphastar Pharmaceuticals by 35.1% in the second quarter. Epoch Investment Partners Inc. now owns 1,078,852 shares of the company's stock worth $43,154,000 after purchasing an additional 280,390 shares during the last quarter. American Century Companies Inc. grew its stake in shares of Amphastar Pharmaceuticals by 19.7% during the 2nd quarter. American Century Companies Inc. now owns 740,408 shares of the company's stock valued at $29,616,000 after purchasing an additional 121,764 shares during the period. Millennium Management LLC increased its position in shares of Amphastar Pharmaceuticals by 84.6% during the 2nd quarter. Millennium Management LLC now owns 738,748 shares of the company's stock valued at $29,550,000 after purchasing an additional 338,653 shares during the last quarter. Finally, Boston Trust Walden Corp bought a new position in shares of Amphastar Pharmaceuticals in the 3rd quarter worth approximately $26,189,000. Institutional investors own 65.09% of the company's stock.

Insiders Place Their Bets

In other Amphastar Pharmaceuticals news, Director Floyd F. Petersen sold 3,000 shares of the business's stock in a transaction dated Thursday, September 5th. The shares were sold at an average price of $46.47, for a total value of $139,410.00. Following the completion of the sale, the director now directly owns 75,409 shares of the company's stock, valued at $3,504,256.23. The trade was a 3.83 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, EVP Rong Zhou sold 4,000 shares of the company's stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $48.35, for a total transaction of $193,400.00. Following the completion of the transaction, the executive vice president now owns 118,388 shares in the company, valued at $5,724,059.80. This represents a 3.27 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 31,533 shares of company stock valued at $1,571,652 over the last three months. 27.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

AMPH has been the topic of several recent research reports. StockNews.com downgraded shares of Amphastar Pharmaceuticals from a "buy" rating to a "hold" rating in a research report on Friday, November 1st. Needham & Company LLC reiterated a "hold" rating on shares of Amphastar Pharmaceuticals in a research report on Thursday, August 8th. Finally, Piper Sandler decreased their target price on Amphastar Pharmaceuticals from $71.00 to $66.00 and set an "overweight" rating on the stock in a research note on Thursday, August 8th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the company's stock. Based on data from MarketBeat, Amphastar Pharmaceuticals has a consensus rating of "Hold" and a consensus price target of $63.00.

Amphastar Pharmaceuticals Trading Down 1.0 %

Shares of Amphastar Pharmaceuticals stock traded down $0.45 on Friday, reaching $44.61. The company had a trading volume of 408,672 shares, compared to its average volume of 397,255. The firm has a market cap of $2.14 billion, a price-to-earnings ratio of 14.87, a P/E/G ratio of 0.88 and a beta of 0.82. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. The firm's 50-day moving average price is $48.40 and its two-hundred day moving average price is $44.37. Amphastar Pharmaceuticals, Inc. has a 1 year low of $36.56 and a 1 year high of $65.92.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.